​

Jazz Pharmaceuticals (JAZZ) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

JAZZ Stock Forecast

Jazz Pharmaceuticals (JAZZ) stock forecast, based on 47 Wall Street analysts, predicts a 12-month average price target of $207.86, with a high of $235.00 and a low of $170.00. This represents a 12.10% increase from the last price of $185.43.

$100 $130 $160 $190 $220 $250 High: $235 Avg: $207.86 Low: $170 Last Closed Price: $185.43

JAZZ Stock Rating

Jazz Pharmaceuticals stock's rating consensus is Buy, based on 47 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 41 Buy (87.23%), 6 Hold (12.77%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 47 0 6 41 Strong Sell Sell Hold Buy Strong Buy

JAZZ Price Target Upside V Benchmarks

TypeNameUpside
StockJazz Pharmaceuticals12.10%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%
IdeaCannabis Stocks List103.65%

Price Target Trends

1M3M12M
# Anlaysts1314
Avg Price Target$224.00$228.00$192.43
Last Closing Price$185.43$185.43$185.43
Upside/Downside20.80%22.96%3.78%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26592--16
Feb, 265101--16
Jan, 264102--16
Dec, 254103--17
Nov, 256111--18
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 09, 2026Etzer DaroutBarclays$224.00$185.4020.82%20.80%
Jan 12, 2026Ami FadiaNeedham$235.00$161.1345.84%26.73%
Jan 08, 2026Sean LaamanMorgan Stanley$225.00$169.3732.85%21.34%
Dec 10, 2025David AmsellemPiper Sandler$219.00$162.2634.97%18.10%
Nov 24, 2025Ashwani VermaUBS$188.00$176.936.26%1.39%
Nov 17, 2025RBC Capital$194.00$170.1414.02%4.62%
Nov 17, 2025Sean LaamanMorgan Stanley$205.00$170.1620.47%10.55%
Oct 24, 2025Morgan Stanley$183.00$137.9732.64%-1.31%
Oct 22, 2025Wells Fargo$170.00$137.5023.64%-8.32%
Oct 20, 2025Morgan Stanley$180.00$137.0731.32%-2.93%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 09, 2026BarclaysOverweightOverweighthold
Jan 29, 2026Cowen & Co.BuyBuyhold
Jan 12, 2026NeedhamBuyBuyhold
Jan 08, 2026Morgan StanleyOverweightOverweighthold
Jan 06, 2026RBC CapitalOutperformOutperformhold
Dec 10, 2025Piper SandlerOverweightOverweighthold
Nov 24, 2025UBSBuyNeutraldowngrade
Nov 17, 2025RBC CapitalOutperformOutperformhold
Nov 17, 2025Morgan StanleyOverweightOverweighthold
Oct 20, 2025Morgan StanleyOverweightOverweighthold

Financial Forecast

EPS Forecast

$-10 $-1 $8 $17 $26 $35 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.51$-3.58$6.55$9.06$-5.84---
Avg Forecast$15.67$13.56$18.50$20.21$21.88$22.40$25.00$26.78
High Forecast$16.42$14.21$18.73$20.49$23.81$26.66$31.99$28.52
Low Forecast$14.81$12.76$18.16$19.74$19.59$16.18$14.90$25.04
Surprise %-135.16%-126.40%-64.59%-55.17%-126.69%---

Revenue Forecast

$3B $3B $4B $4B $5B $6B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.09B$3.66B$3.83B$4.07B$4.27B---
Avg Forecast$3.06B$3.66B$3.83B$4.04B$4.31B$4.48B$4.76B$5.04B
High Forecast$3.18B$3.79B$3.93B$4.06B$4.53B$4.49B$4.78B$5.30B
Low Forecast$2.93B$3.49B$3.78B$4.01B$4.10B$4.46B$4.73B$4.79B
Surprise %1.04%0.00%0.02%0.76%-0.98%---

Net Income Forecast

$-500M $100M $700M $1B $2B $3B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-328.95M$-224.06M$414.83M$560.12M$-356.15M---
Avg Forecast$1.13B$177.38M$414.83M$1.45B$1.56B$1.54B$1.69B$1.93B
High Forecast$1.18B$226.81M$530.42M$1.48B$1.72B$1.92B$2.31B$2.06B
Low Forecast$1.07B$127.96M$299.25M$1.42B$1.41B$1.17B$1.07B$1.80B
Surprise %-129.13%-226.31%--61.36%-122.77%---

JAZZ Forecast FAQ

Is Jazz Pharmaceuticals stock a buy?

Jazz Pharmaceuticals stock has a consensus rating of Buy, based on 47 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 41 Buy, 6 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Jazz Pharmaceuticals is a favorable investment for most analysts.

What is Jazz Pharmaceuticals's price target?

Jazz Pharmaceuticals's price target, set by 47 Wall Street analysts, averages $207.86 over the next 12 months. The price target range spans from $170 at the low end to $235 at the high end, suggesting a potential 12.10% change from the previous closing price of $185.43.

How does Jazz Pharmaceuticals stock forecast compare to its benchmarks?

Jazz Pharmaceuticals's stock forecast shows a 12.10% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%), trailing the Cannabis Stocks List (103.65%) investment idea.

What is the breakdown of analyst ratings for Jazz Pharmaceuticals over the past three months?

  • March 2026: 31.25% Strong Buy, 56.25% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 31.25% Strong Buy, 62.50% Buy, 6.25% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 25.00% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.

What is Jazz Pharmaceuticals’s EPS forecast?

Jazz Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $22.4, marking a -483.56% decrease from the reported $-5.84 in 2025. Estimates for the following years are $25 in 2027, and $26.78 in 2028.

What is Jazz Pharmaceuticals’s revenue forecast?

Jazz Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $4.48B, reflecting a 4.94% increase from the reported $4.27B in 2025. The forecast for 2027 is $4.76B, and $5.04B for 2028.

What is Jazz Pharmaceuticals’s net income forecast?

Jazz Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $1.54B, representing a -533.44% decrease from the reported $-356M in 2025. Projections indicate $1.69B in 2027, and $1.93B in 2028.